Sponsors (7)
The bill strengthens federal oversight, traceability, and coordinated response to biosafety and biosecurity risks—but does so by imposing new compliance costs, expanding collection of sensitive identity/location data (raising privacy and security concerns), and limiting public transparency.
State, local, Tribal, and territorial public-health officials get a single federal point of contact plus access to standardized transfer/log and lab-location information, enabling faster, better-coordinated responses to lab incidents, accidental releases, and other public‑health emergencies.
Researchers, hospitals, and distributors will be subject to standardized electronic logbooks and identity-verification requirements that improve traceability and accountability of transfers of high‑risk biological agents, helping detect, deter, and stop suspicious or illicit acquisition or diversion.
Regular strategic evaluations and new national standards for laboratory design, operation, and oversight (plus a feasibility study for a centralized lab information resource) can identify gaps and drive improvements that reduce biosafety/biosecurity risks and prevent accidents.
Covered distributors, biobanks, lab owners, and research institutions will face new and potentially substantial compliance costs and administrative burdens to implement Secretary‑specified electronic logbooks, verification, and to meet national oversight standards.
Expanded collection and centralized storage of purchaser and facility identity/address information — plus criminal penalties for false statements — raise privacy, legal exposure, and security risks for researchers, purchasers, and facility owners and could chill legitimate research activity.
Broad FOIA exemptions and restricted access to transfer and biosurveillance data reduce public transparency and independent oversight, limiting accountability for program implementation and use of sensitive data.
Based on analysis of 3 sections of legislative text.
Introduced October 14, 2025 by Jim Costa · Last progress October 14, 2025
Requires federal tracking of transfers of a newly defined set of “highly pathogenic agents” by making distributors keep standardized electronic logbooks that record buyer identity, intended use, location, and transaction details; limits public release of those records and applies criminal false‑statement notices and retention rules. Also directs the National Security Advisor to pick one federal entity to run regular strategic evaluations of high‑containment (BSL‑3+) laboratories, create national design and operation standards, stand up a single public‑health contact team, and study the feasibility of a national lab database.
Mandates federal tracking of transfers of listed "highly pathogenic agents," requires distributor electronic logbooks with restricted disclosure, and orders enhanced federal oversight of high‑containment labs.